Global research-based biopharmaceutical company AbbVie has announced U.S FDA approval for their new therapy for adults with moderately to severely active rheumatoid arthritis (RA). RINVOQ is a once-daily (15mg) oral Janus kinase inhibitor supported by data from the SELECT program - one of the largest registrational Phase 3 programs in RA. Approximately 4,400 patients were evaluated across all treatment arms in five studies. The company says that RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal. https://urlzs.com/SxYV2
Insulin pumps have been around for the past decade, aiding type 1 diabetics in controlling their blood glucose levels. Previous pumps have required manual input for it to administer insulin. Recent developments of the closed loop system mean you are only required to add of discrete amount of insulin within a specific time that corresponds to the amount of carbs you are about to consume. The closed loop system then continues to monitor your blood sugar level throughout the day, automatically administering slightly more insulin as levels rise, and reducing the amount when levels lower. There are many ways to wear the pump. You can attach it to your belt, protect it in your pocket, or even clip it under your clothing.?https://diabetesnsw.com.au/helpful-resources/
Australian company Nanosonics have launched the latest innovation in ultrasound probe high-level disinfection: Trophon?2. A fully automated process for the decontamination of ultrasound probes, Trophon2 is safe for the environment, users and most importantly patients. Full decontamination and traceability occurs within seven minutes with the press of a button. https://www.nanosonics.com.au/trophon2/
This app by PainChek is designed to help with identifying the health problems in infants and children who are unable to communicate their medical symptoms and pain to health professionals. With the use of facial recognition technology, the app is able to detect and analyse any pain and signals with just the slightest change of facial expression by the child. This would be great help for medical staff and hospitals who have difficulty identifying specific and accurate problems which will reduce the risk of misdiagnosis. https://neweconomy.media/2019/08/05/app-to-reveal-unspoken-pain-in-kids/
Australia-based gut health biotech company Microba has launched a research and development program to develop gut microbiome derived therapeutics for IBD. Microba has identified distinct differences in the gut microbiome of healthy individuals and those with IBD. Using deep learning artificial intelligence, their scientists are now able to predict IBD in patients from microbiome data alone with 86% accuracy. The program aims to create novel therapeutics that will rapidly induce and maintain remission in those with IBD. Microba launched the program at BIO in Philadelphia with the Queensland Minister for Innovation, The Hon. Kate Jones in June. | http://bit.ly/2T5B37F
Female doctors are in short supply in Pakistan despite women making up 70% of all medical students. This is because what is known as the "doctor bride" phenomenon; women in Pakistan who have medical degrees but stop practising to look after their children and/or because of social pressure. These doctors are desperately needed as 50% of the total Pakistani population lacks access to a doctor in their community. Sehat Kahani is the solution. Trained female doctors work from home using telemedicine and consult with patients in remote areas who come to an E-Health clinic. https://sehatkahani.com/
